India Pharma Outlook Team | Saturday, 16 August 2025
SCHOTT, the world leader in specialty glass production, has expanded its manufacturing plant in Jambusar, Gujarat, introducing Syringe and cartridge glass tubing made in India. This transforms SCHOTT into the biggest provider of syringe and cartridge glass tubing in the Asian region, and India becomes even more self-reliant in terms of superior pharmaceutical packaging.
The new production line, which has been relocated directly to the factory of SCHOTT in Germany, has been optimized to handle the growth in terms of demand of both advanced drug delivery systems and more specifically, the biologics market. One of them is the GLP-1 receptor agonist (semaglutide), which is broadly utilized in type 2 diabetes and weight control-related treatment plans, and this field is estimated to increase at a rate of 33 percent compound yearly.
Through this milestone, SCHOTT offers a comprehensive local supply of glass primary packaging in India that comprises of vials, ampoules, prefillable syringes and cartridges.
“This marks an important step in strengthening India’s pharmaceutical infrastructure,” said Sundeep Prabhu, Senior Vice President of Sales & Marketing at SCHOTT Glass India. “As the first company to manufacture this category of glass tubing locally, we’re enhancing our production capabilities while contributing to India’s healthcare resilience. Our investment is aligned with the ‘Make in India’ vision and supports the country’s long-term economic and industrial growth.”
Also Read: How PLI Scheme is Reshaping India's Drug Production Future
The company’s FIOLAX® Type I borosilicate glass is globally recognized for high chemical resistance, precision, and consistent quality. “Our focus isn’t only on increasing capacity—it’s on building long-term reliability for critical drug delivery components,” said Pawan Kumar Shukla, President & Managing Director of SCHOTT Glass India. “By producing FIOLAX® syringe and cartridge tubing locally,a and using technologies like our perfeXion® quality system that analyzes 100,000 data points per minute, we aaim to deliver top-tier quality with zero-defect standards.”
SCHOTT’s expansion reflects India’s rapid pharma growth, skilled talent base, and supportive policy ecosystem while reinforcing supply chain stability for the region.
